A well-regarded chain of buprenorphine treatment operations has agreed to pay a civil settlement in a case that in part speaks to concerns about the mix of services in medication-assisted treatment facilities.
Christopher Bathum, founder of 19 sober-living facilities in California and Colorado, faces multiple charges of sexually assaulting patients, as well as engaging in a $175 million insurance fraud scheme.
With possible revisions to buprenorphine prescribing limits looming, respondents to an American Society of Addiction Medicine (ASAM) survey report increasing difficulty in meeting demand for the opioid addiction treatment.
A group of experts that convened last year to address the prescription opioid crisis has formally issued recommendations that include mandated use of prescription drug monitoring programs (PDMPs) by providers.
Drug testing company Calloway Laboratories, which in recent years had been embroiled in controversies over improper government payments, is citing "unforeseen circumstances" in its decision to cease operation on Oct. 16.